Lung Cancers Completed Phase 2 Trials for Cetuximab (DB00002)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00673738Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)Treatment
NCT00323869Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung CancerTreatment
NCT00124618Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment
NCT00193453Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerTreatment
NCT00103207Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung CancerTreatment
NCT00117962Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment
NCT00081302Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung CancerTreatment
NCT00085501S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment